• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Diffuse midline glioma treated with epigenetic agent-based immunotherapy.

作者信息

Jing Linkai, Qian Zhihong, Gao Qiang, Sun Rui, Zhen Zili, Wang Guihuai, Yang Xuejun, Li Haitao, Guo Tiannan, Zhang Wei

机构信息

Department of Neurosurgery, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, People's Republic of China.

Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, People's Republic of China.

出版信息

Signal Transduct Target Ther. 2023 Jan 20;8(1):23. doi: 10.1038/s41392-022-01274-7.

DOI:10.1038/s41392-022-01274-7
PMID:36658142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9852273/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b902/9852273/f97bf9ce07ff/41392_2022_1274_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b902/9852273/f97bf9ce07ff/41392_2022_1274_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b902/9852273/f97bf9ce07ff/41392_2022_1274_Fig1_HTML.jpg

相似文献

1
Diffuse midline glioma treated with epigenetic agent-based immunotherapy.采用基于表观遗传药物的免疫疗法治疗弥漫性中线胶质瘤。
Signal Transduct Target Ther. 2023 Jan 20;8(1):23. doi: 10.1038/s41392-022-01274-7.
2
Integrated analysis of pediatric low-grade glioma: clinical implications and the path forward.小儿低级别胶质瘤的综合分析：临床意义与未来方向
Neuro Oncol. 2020 Oct 14;22(10):1413-1414. doi: 10.1093/neuonc/noaa187.
3
Emerging Epigenetic Therapies for Brain Tumors.脑肿瘤的新兴表观遗传学疗法。
Neuromolecular Med. 2022 Mar;24(1):41-49. doi: 10.1007/s12017-021-08691-x. Epub 2021 Oct 22.
4
Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma.伴有H3F3A K27M突变的弥漫性非中线胶质瘤：预后与治疗困境
Acta Neuropathol Commun. 2017 May 15;5(1):38. doi: 10.1186/s40478-017-0440-x.
5
Emerging interplay of genetics and epigenetics in gliomas: a new hope for targeted therapy.胶质瘤中遗传学与表观遗传学的新兴相互作用：靶向治疗的新希望。
Semin Pediatr Neurol. 2015 Mar;22(1):14-22. doi: 10.1016/j.spen.2014.12.004. Epub 2014 Dec 11.
6
Epigenetic changes in gliomas.胶质瘤中的表观遗传变化。
Cancer Biol Ther. 2008 Sep;7(9):1326-34. doi: 10.4161/cbt.7.9.6992. Epub 2008 Sep 18.
7
[Adult diffuse glioma: genetic heterogeneity and therapeutic implications].[成人弥漫性胶质瘤：基因异质性及其治疗意义]
Med Sci (Paris). 2012 Oct;28(10):813-6. doi: 10.1051/medsci/20122810005. Epub 2012 Oct 12.
8
Molecular biology of glioma.神经胶质瘤的分子生物学。
Adv Exp Med Biol. 2012;746:2-11. doi: 10.1007/978-1-4614-3146-6_1.
9
Epigenetic markers in human gliomas: prospects for therapeutic intervention.人类胶质瘤中的表观遗传标记：治疗干预的前景
Expert Rev Neurother. 2008 Oct;8(10):1475-96. doi: 10.1586/14737175.8.10.1475.
10
Pediatric low-grade gliomas: how modern biology reshapes the clinical field.小儿低级别胶质瘤：现代生物学如何重塑临床领域
Biochim Biophys Acta. 2014 Apr;1845(2):294-307. doi: 10.1016/j.bbcan.2014.02.004. Epub 2014 Feb 28.

引用本文的文献

1
Modern treatment of malignant spinal cord astrocytomas: a review article.恶性脊髓星形细胞瘤的现代治疗：一篇综述文章。
Med Oncol. 2025 Jul 23;42(8):369. doi: 10.1007/s12032-025-02915-x.
2
Epigenetic reprogramming and antitumor immune responses in gliomas: a systematic review.胶质瘤中的表观遗传重编程与抗肿瘤免疫反应：一项系统综述
Med Oncol. 2025 May 16;42(6):213. doi: 10.1007/s12032-025-02760-y.
3
Aneurysmal formation of periventricular anastomosis is associated with collateral development of Moyamoya disease and its rupture portends poor prognosis: detailed analysis by multivariate statistical and machine learning approaches.

本文引用的文献

1
Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.帕比司他治疗携带H3 K27M突变的成人弥漫性中线胶质瘤：单中心经验
J Neurooncol. 2022 Mar;157(1):91-100. doi: 10.1007/s11060-022-03950-8. Epub 2022 Jan 25.
2
Hallmarks of Cancer: New Dimensions.癌症的特征：新视角。
Cancer Discov. 2022 Jan;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059.
3
Leptomeningeal disease in glioblastoma: endgame or opportunity?胶质母细胞瘤中的脑膜疾病：终局还是机会？
室周吻合动脉瘤形成与烟雾病侧支发育有关，其破裂预示预后不良：多变量统计和机器学习方法的详细分析。
Neurosurg Rev. 2024 Nov 19;47(1):856. doi: 10.1007/s10143-024-03097-2.
4
Advances in Molecular Pathology, Diagnosis and Treatment of Spinal Cord Astrocytomas.脊髓星形细胞瘤的分子病理学、诊断和治疗进展。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241262483. doi: 10.1177/15330338241262483.
5
Usefulness of magnetic resonance imaging characteristics in discriminating H3 K27M-mutant gliomas from wildtype gliomas in spinal cord.磁共振成像特征在鉴别脊髓中 H3 K27M 突变型胶质瘤与野生型胶质瘤中的作用
Neurol Sci. 2024 Jun;45(6):2845-2851. doi: 10.1007/s10072-024-07315-z. Epub 2024 Jan 16.
6
Long-term survival after cordectomy in a case of spinal cord diffuse midline glioma, H3K27-altered: illustrative case.脊髓弥漫性中线胶质瘤（H3K27改变）行脊髓切除术术后长期生存：病例说明
J Neurosurg Case Lessons. 2023 Dec 18;6(25). doi: 10.3171/CASE23296.
7
Molecular Characterization and Treatment Approaches for Pediatric -Altered Diffuse Midline Glioma: Integrated Systematic Review of Individual Clinical Trial Participant Data.儿童变异型弥漫性中线胶质瘤的分子特征及治疗方法：个体临床试验参与者数据的综合系统评价
Cancers (Basel). 2023 Jul 3;15(13):3478. doi: 10.3390/cancers15133478.
J Neurooncol. 2021 Nov;155(2):107-115. doi: 10.1007/s11060-021-03864-x. Epub 2021 Oct 8.
4
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.帕博利珠单抗治疗脑脊髓转移癌患者的单臂、开放标签 2 期临床试验。
Nat Med. 2020 Aug;26(8):1280-1284. doi: 10.1038/s41591-020-0918-0. Epub 2020 Jun 2.
5
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.EZH2 是 H3K27M 突变型小儿脑胶质瘤的潜在治疗靶点。
Nat Med. 2017 Apr;23(4):483-492. doi: 10.1038/nm.4293. Epub 2017 Feb 27.